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Rearrangement of the anaplastic lymphoma kinase (ALK) gene is oncogenic in approx-imately 5% of lung adenocarcinomas.1 Identifying patients with this tumor subtype 
is important because they can significantly benefit from small-molecule ALK inhibitor 
therapy.2 Fluorescence in situ hybridization (FISH) is considered the standard test for this 
purpose and was the modality used in clinical trials to determine eligibility.2 At present, the 
Vysis ALK Break Apart FISH probe (Abbott Molecular, Abbott Park, IL ) is the only com-
panion diagnostic kit approved by the US Food and Drug Administration. However, other 
methods are also available, with ALK immunohistochemistry (IHC) considered particularly 
promising for clinical use, as it can detect ALK protein overexpressed as a result of gene 
fusion in a rapid and cost-effective manner. Nonetheless, there are challenges in using FISH 
and IHC for diagnosing lung cancers with ALK rearrangement. For the break-apart FISH 
assay, the primary difficulty is interpretational, such as distinguishing between narrow split 
signals in ALK-rearranged tumors arising from the proximity of ALK and its frequent part-
ner echinoderm microtubule-associated protein like 4 (EML4), occasional split signals in 
ALK wild-type tumors, and admixtures of non-neoplastic elements that may dilute the sig-
nal from abnormal cells in a dark field. This can be mitigated to some extent by strict adher-
ence to enumeration rules. In contrast, major difficulties associated with ALK IHC are 
technical in nature. Well-established, conventional methods using the ALK1 antibody clone 
have unacceptably low levels of sensitivity ranging from 9% to 67%,3,4 whereas excessive 
signal enhancement and increased antibody concentration result in reduced specificity and 
high background signal.3,4 To overcome these limitations, improved staining protocols have 
been developed by several groups; these involved the use of alternative primary antibodies 
(e.g., 5A4 and D5F3) and/or specific signal amplification steps.3–8
With ALK testing for lung cancers becoming the standard of care worldwide, there is 
growing interest in extending its benefits to different regions and communities. Test stan-
dardization and quality control issues have emerged at the center of this discussion. In this 
issue of Journal of Thoracic Oncology, Cutz et al.9 describe a promising model for quality 
assurance in ALK testing through the formation of a pathology network in the Canadian 
ALK (CALK) study. This structurally complex study had three phases. In phases 1 and 2, 
control tissue microarray slides with multiple cases of known ALK status were compiled 
and distributed to more than 10 institutions for FISH and locally developed IHC analyses. 
The results were analyzed, and feedback was provided so as to assist each center in optimiz-
ing its own IHC protocol. In phase 3, 373 cases of lung cancer were evaluated concurrently 
by postoptimized IHC and FISH at three centers; a perfect concordance was observed in 
the results obtained by the two methods if equivocal IHC staining was considered negative.
This study is distinguished from other multi-institutional standardization efforts in 
ALK testing (summarized by Yatabe et al.10) by the inclusion of a protocol adjustment 
phase. Beyond publishing the results of initial round-robin tests, the CALK authors 
took active measures to improve staining methods at each institution. As a result, high 
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background staining largely disappeared, and the interclass 
correlation coefficient for the 5A4 clone increased from 0.867 
to 0.949. Parenthetically, such improvement alone provides 
evidence for the limitations of developing local methods 
based on publications. This type of dynamism is unprece-
dented; in earlier studies that compared ALK FISH and IHC, 
the staining protocol had already been established in-house, 
and it was unclear how they were previously optimized and 
whether they could be further improved. Another advantage 
of this study was that it used multiple clinical control samples 
rather than a single case or cell line, which allowed for fine 
adjustment of staining conditions. The CALK strategy is also 
notable for its technical flexibility in facilitating the optimi-
zation of existing approaches rather than enforcing a single, 
uniform, “authorized” method. Although there was a clear 
preference for the 5A4 clone over ALK1 or D5F3 and it was 
the only antibody that was prospectively validated, the CALK 
study demonstrated the feasibility of standardizing the effect 
without standardizing the means. Taken together, the CALK 
study provides an efficient and realistic model for establishing 
a diagnostic standard at the community level.
Because IHC optimization thus obtained is arguably the 
most rigorous in the literature, the results should allow a pre-
diction of what is expected if the process is completed. For 
example, the CALK study provides insight into an appropri-
ate interpretative cutoff for IHC; staining results were binary 
and expressed as either unambiguously positive or negative 
in most instances, with a few samples (7.6%) having faint, 
focal staining or high background.9 In unequivocally positive 
cases, practically all tumor cells were stained and the stain-
ing intensity, if diffuse, did not make a significant difference 
to the interpretation. These results, in agreement with several 
previous studies,6–8,11 are consistent with the notion that ALK 
fusion acts as an early driver for oncogenesis and do not sup-
port the use of a semiquantitative grading system of the kind 
currently applied to HEr2 IHC for breast cancers.
Another example is the achieved diagnostic accuracy of 
IHC, which was superior to that of FISH in the CALK study.9 
Specifically, one control case (CALK-11) in phase 2 with a 
discordant (IHC−/FISH+) result was reanalyzed by FISH and 
showed an atypical signal pattern that was uninterpretable by 
current criteria; reverse transcription quantitative polymerase 
chain reaction and rNA sequencing failed to detect any ALK 
fusions that confirmed the IHC result. Similarly, in all three 
cases that initially showed discordant results in phase 3, the 
original finding was contradicted after repeating the FISH 
testing. The initial discordance was not due to imperfect IHC 
performance; the study highlighted the importance of criti-
cally reanalyzing FISH data in such instances. Although FISH 
is a powerful diagnostic tool that allows the direct visualiza-
tion of genomic changes, it is not without flaws. A small but 
increasing number of reports have documented falsely posi-
tive or negative errors in ALK FISH assays that were either 
biological or interpretative. Biologically based errors occur 
when FISH yields atypical signals (as in CALK-119) that defy 
interpretation5,8,12,13 or typical but incorrect patterns,5,6,11,14,15 
and they are likely attributable to complex and/or cryptic 
genomic alterations. The other, perhaps more common, cause 
of inaccuracy is signal misinterpretation. Although the sub-
stantial variability in FISH scoring (interclass correlation 
coefficient = 0.68) in the CALK study was diminished when 
scores were translated to the final dichotomous reading in 
relation to the 15% cutoff value, there were still 14 misin-
terpretations (11 false negatives and three false positives) of 
317 readings (4.4%). Given that this assay was performed by 
experienced technicians who had already undergone specific 
hands-on training by the assay manufacturer,9 it remains to 
be determined whether there is room for future improvements 
in FISH by proficiency testing. Similar errors have also been 
sporadically reported by others.3,7,16
How will the optimized ALK IHC change the landscape 
of ALK testing in thoracic oncology? At a minimum, it can 
complement results obtained by FISH. Having reliable IHC 
as a backup modality is particularly useful when FISH fails 
(9.2% of cases in phase 3 of the CALK study9 but up to 26%7 
of cases in the literature), shows atypical signal patterns (the 
incidence of which is undetermined), or when scores fall in 
a borderline category (e.g., the abnormal cell range of 10–
20% that was observed in 5.4% of cases in phase 3 of the 
CALK study). Furthermore, as the CALK study authors pro-
posed, IHC can serve as an effective screening tool, with FISH 
used in cases where IHC results are unambiguously positive 
or equivocal; this strategy is already in place in Canada and 
other countries. Finally, optimized IHC may assume the diag-
nostic role, with FISH testing entirely omitted when there is 
clear staining and used only as an adjunct when IHC results 
are deemed inconclusive by pathologists. Although this prac-
tice may not be globally adopted until clinical trials in which 
cohorts are primarily defined by optimized IHC have proven 
to be successful, the 100% accuracy that was demonstrated for 
IHC by the CALK study encourages a paradigm shift in that 
direction. This is desirable in our opinion, in an era where a 
growing need for ALK testing warrants a method that is not 
restricted by high cost, intense labor, long turn-around time, 
occasional failure, and limited access. Multi-institutional ini-
tiatives for staining quality standardization, as exemplified by 
the CALK study, should accelerate this change. Additional 
requirements to that end include accreditation of laboratories 
that have completed staining optimization and a system that 
ensures periodic quality control. Wider publication is also 
needed to enhance awareness of the few inherent pitfalls of 
ALK IHC, such as the occasional detection of full-length 
ALK in high-grade neuroendocrine carcinomas.15 With all 
these in place, ALK IHC may finally unleash its full potential 
as an optimized armor in the battle against lung cancers.
REFERENCES
 1. Soda M, Choi YL, Enomoto M, et al. Identification of the transform-
ing EML4-ALK fusion gene in non-small-cell lung cancer. Nature 
2007;448:561–566.
 2. Kwak EL, Bang YJ, Camidge Dr, et al. Anaplastic lymphoma kinase inhi-
bition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–1703.
 3. Mino-Kenudson M, Chirieac Lr, Law K, et al. A novel, highly sensi-
tive antibody allows for the routine detection of ALK-rearranged lung 
adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 
2010;16:1561–1571.
1239Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014 Editorial
 4. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion onco-
kinase identified by an immunohistochemistry-based diagnostic system 
for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143–3149.
 5. Houang M, Toon CW, Clarkson A, et al. reflex ALK immunohistochem-
istry is feasible and highly specific for ALK gene rearrangements in lung 
cancer. Pathology 2014;46:383–388.
 6. To KF, Tong JH, Yeung KS, et al. Detection of ALK rearrangement by 
immunohistochemistry in lung adenocarcinoma and the identification of 
a novel EML4-ALK variant. J Thorac Oncol 2013;8:883–891.
 7. Minca EC, Portier BP, Wang Z, et al. ALK status testing in non-small cell 
lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol 
Diagn 2013;15:341–346.
 8. Yoshida A, Tsuta K, Nitta H, et al. Bright-field dual-color chromogenic 
in situ hybridization for diagnosing echinoderm microtubule-associated 
protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcino-
mas. J Thorac Oncol 2011;6:1677–1686.
 9. Cutz J-C, Craddock KJ, Torlakovic E, et al. Canadian Anaplastic Lymphoma 
Kinase (CALK) study: a model for multi-centre standardization and optimi-
zation of ALK testing in lung cancer. J Thorac Oncol 2014;9:1255–1263.
 10. Yatabe Y, Lantuéjoul S, Thunnissen E, et al. Guidelines and stan-
dardization studies. In: Tsao MS, Hirsch Fr, Yatabe Y (Eds). IASLC 
Atlas of ALK Testing in Lung Cancer. Aurora, Co: IASLC Press, 
2013:61–66.
 11. Ying J, Guo L, Qiu T, et al. Diagnostic value of a novel fully automated 
immunochemistry assay for detection of ALK rearrangement in primary 
lung adenocarcinoma. Ann Oncol 2013;24:2589–2593.
 12. Peled N, Palmer G, Hirsch Fr, et al. Next-generation sequencing iden-
tifies and immunohistochemistry confirms a novel crizotinib-sensitive 
ALK rearrangement in a patient with metastatic non-small-cell lung can-
cer. J Thorac Oncol 2012;7:e14–e16.
 13. ren S, Hirsch Fr, Varella-Garcia M, et al. Atypical negative ALK break-
apart FISH harboring a crizotinib-responsive ALK rearrangement in non-
small-cell lung cancer. J Thorac Oncol 2014;9:e21–e23.
 14. Selinger CI, rogers TM, russell PA, et al. Testing for ALK rearrange-
ment in lung adenocarcinoma: a multicenter comparison of immu-
nohistochemistry and fluorescent in situ hybridization. Mod Pathol 
2013;26:1545–1553.
 15. Murakami Y, Mitsudomi T, Yatabe Y. A Screening Method for the ALK 
Fusion Gene in NSCLC. Front Oncol 2012;2:24.
 16. Sholl LM, Weremowicz S, Gray SW, et al. Combined use of ALK immu-
nohistochemistry and FISH for optimal detection of ALK-rearranged 
lung adenocarcinomas. J Thorac Oncol 2013;8:322–328.
